Earnings Feed
Start Free
Kalaris Therapeutics, Inc.·4

May 22, 7:47 PM ET

AKKARAJU SRINIVAS 4

Research Summary

AI-generated summary

Updated

Kalaris (KLRS) 10% Owner Dr. Srinivas Akkaraju Buys 244,300 Shares

What Happened
Dr. Srinivas Akkaraju (reported as a 10% owner) purchased 244,300 shares of Kalaris Therapeutics (KLRS) on May 20, 2026 at $4.83 per share for a total of $1,179,969. That acquisition was a privately negotiated purchase from Samsara BioCapital, L.P. (Samsara LP) (transaction code P). The filing also reports J-coded “other acquisition/disposition” entries on the same date: a disposition of 66,906 shares and acquisitions of 14,937 and 4,471 shares at no cash consideration — these reflect in‑kind distributions among related Samsara entities, not cash trades.

Key Details

  • Transaction date(s): May 20, 2026. Purchase price: $4.83/share for 244,300 shares (total $1,179,969). (P = purchase)
  • J-coded entries: 66,906 shares disposed; 14,937 and 4,471 shares acquired at $0 — these are pro rata, in‑kind distributions by Samsara LP (no cash exchanged).
  • Beneficial ownership notes: Several footnotes state the shares are held by affiliated Samsara funds/entities. Dr. Akkaraju has voting and investment power over some of those entities and “may be deemed” to beneficially own the shares, but each reporting person disclaims ownership except to the extent of pecuniary interest.
  • Filing timeliness: Report filed May 22, 2026 for transactions on May 20, 2026 — appears timely (filed within the typical two-business-day window).
  • Shares owned after the transaction: Not specified in the summary data of this filing.

Context

  • The primary item is a private purchase from an affiliated investor (Samsara LP), which is more informative than routine sales because it shows a cash purchase of company stock.
  • The J-coded transfers are internal, in‑kind allocations among Samsara-related entities (not market sales or purchases) and do not necessarily reflect personal trading intent.
  • As a reported 10% owner acting through/with affiliated funds, these transactions reflect institutional/fund-level movements and related transfer mechanics; they should be viewed differently from typical executive open‑market trades.